| Autor: |
Anna Solé‐Porta, Aina Areny‐Balagueró, Marta Camprubí‐Rimblas, Elena Fernández Fernández, Andrew O’Sullivan, Rossella Giannoccari, Ronan MacLoughlin, Daniel Closa, Antonio Artigas, Anna Roig |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Small Science, Vol 4, Iss 9, Pp n/a-n/a (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2688-4046 |
| DOI: |
10.1002/smsc.202400066 |
| Popis: |
Acute respiratory distress syndrome (ARDS) is a clinical syndrome characterized by acute hypoxemic respiratory failure. Pneumonia and sepsis are the most common causes, turning ARDS into a critical public health problem. Despite recent advances in pharmacological strategies, clinical trials have not demonstrated a reduction in ARDS‐associated mortality. This is in part connected to the singularity of the pulmonary physiological barrier, which hampers drug delivery, specifically at distal areas. To this aim, the use of polymeric nanocarriers as a platform for the efficient delivery of therapeutics to the lungs by nebulization is introduced. Herein, poly(lactic‐co‐glycolic acid) (PLGA) nanocapsules (NCs) loaded with human serum albumin, as an inhalable nanotherapeutic are prepared. The production of stable NCs aerosols in the inhalable range is achieved using a commercial device, while the nanocarrier's physicochemical parameters are only minimally altered after nebulization. Importantly, in vivo studies with healthy and acute lung injury animals show that after inhalation, the NCs are homogeneously distributed throughout the lungs, arriving at the distal areas. The NCs are internalized by alveolar type II cells, avoiding macrophage‐mediated lung clearance. These features make the PLGA NCs excellent vehicles for noninvasive pulmonary delivery, facilitating a ready‐to‐be‐used nanomedicine. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text